Ann: AusCann Appoints Advisor, Suspends Small Share Sale Facility, page-13

Tick Tock...Tick Tock...
We are not alone and not pursuing a unique path... this was in the AFR today....
Good for the industry as a whole but for more companies following our pharmaceutical path...interesting...ScotttheRatbag hopefully our proprietary capsule delivery system is a large enough moat???

Billionaire families including the Libermans, Smorgons and Waislitzs are backing an early stage producer of medical cannabis for clinical trials, plant science and eventually the pharmaceutical industry.CannaPacific is hoping to capitalise on the increasing acceptance of the medical cannabis industry, which is tipped to reach $US1.2 billion ($1.7 billion) in value by 2024.Medical conditions where cannabinoids, or CBD, is used mostly relate to pain management. CBD can be obtained through an authorised prescriber or the Special Access Scheme in Australia.
Cornerstone investor Aleafia Health of Canada was also an early backer and controls 10 per cent of CannaPacific. Mr Gunning is expecting that Aleafia will follow its money by providing medical cannabis product such as oils and sprays to CannaPacific, which it then sells to patients through general practitioners.
"Our first stream is to cultivate and provide product to others, whilst developing our unique varieties (of plants) with our partnerships with Tasmanian Alkaloids, the University of Newcastle and Xing Technology.
Mr Dennis, who founded the company in 2016 and is a civil and structural engineer, has a lofty goal of becoming the next GW Pharmaceuticals – a British group listed in the US with a $US3 billion market capitalisation. It is a global leader in developing cannabinoid-based registered medicines.